Aleor Dermaceuticals, Lidocaine, and Prilocaine topical cream is approved by the US Food and Drug Administration

thereference listed drug product EMLA Cream, 2.5%/2.5%, of Teva Branded Pharmaceutical Products R&D, Inc. Lidocaine 2.5 per cent and Prilocaine 2.5 per cent cream (a eutectic mixture of lidocaine 2.5 per cent and prilocaine 2.5 per cent ) is indicated as a topical anaesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anaesthesia.

The cream is not suggested in any clinical situation when penetration or migration beyond the tympanic membrane into the middle ear is possible because of the ototoxic effects observed in animal studies Lidocaine and Prilocaine Cream USP 2.5 per cent / 2.5 per cent, has an estimated market size of US$29 million for twelve months ending Dec. 2021 according to IQVIA.